There have been few extensive studies on TIL therapy for NSCLC; despite the potential responsiveness of this malignancy to PD-1/PD-L1 inhibitors and its high mutational burden, TIL therapy may be an appropriate therapeutic option. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.